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A41-year-oldwomanwithahistoryofHodgkindisease inheradolescencewasdiagnosedwith
melanomaof the left upper thigh thatwas classified as American Joint Committee onCancer
(AJCC) stage IIA with (pT3aN0 [sn0/1] M0) BRAFmutation. One year later she underwent
inguinal lymphadenectomy for macrometastasis followed by adjuvant immunotherapy with
ipilimumab, amonoclonal antibody that targets cytotoxic T-lymphocyte antigen 4. Owing to
localdiseaseprogression,treatmentescalationwithcombinedimmunotherapy(ipilimumaband
nivolumab, an anti–PD-1 [programmed cell death 1]) antibody was initiated. Apart from
immunotherapy-inducedthyroiditis, thetreatmentwaswell tolerated.However,after 11cycles
ofnivolumab, thepatientpresentedwithprogressivepainful reddeningandswellingofthe left
thigh.Therewasnodeteriorationofthegeneralcondition,nofever,nochange incurrentmedi-
cation,andnorecentcoldexposure.Clinicalexaminationrevealeddiffuseerythematous indu-
rationof theupper thigh expanding to the lower left abdominal area, aswell asmultiple small
palpablesubcutaneousnoninduratednodulesonthe ipsilateralgluteal regionand leg (Figure,
A). Fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography–computed
tomography (PET-CT)detectedmultipleFDG-active lesions inboth lowerextremities and the
lumbarregion;apreviouslydescribedleft iliac lymphadenopathywaspartiallyregressed(Figure,
B).Adiagnosticbiopsyspecimenoftheleftthighrevealedalobular lymphocyticpanniculitiswith
dense infiltrateofmainly lymphocytesandplasmacellswithnosignsofvasculitis (Figure,Cand
D).Direct immunofluorescenceandbloodanalysisshowedanabsenceofspecificautoimmune
antigens (test results for α-1 antitrypsin, antinuclear antibody, anti-Sjögren syndrome–related
antigen, andanti-Sjögren syndrome–related antigenBwere all unremarkable).
Clinical photographA 18F-FPG PET-CTB Original magnification × 40C
Original magnification × 100D
Figure. A, Localized erythematous brownish induration seen on the upper thigh. Arrowheads correlate with themost prominent clinical findings. B, Radioactive
fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography–computed tomography (PET-CT) reveals multiple subcutaneous lesions in both lower
extremities, the lumbar region, and on the ipsilateral lower leg with high FDG uptake highly suggestive of (in transit) metastasis. C and D, Lesional skin biopsy
samples obtained from the proximal left thigh show normal epidermis and dermis with patchy infiltrate of the deep subcutaneous fat (hematoxylin-eosin stain).
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Immunologic checkpoint blockade has changed the treatment
landscape for advanced melanoma with impressive response and
survival rates,1 but it is associated with a large spectrum of
immune-related toxic effects owing to an increase of the baseline
T-cell–specific immune response.2,3 Skin toxic effects represent
the most common adverse effects associated with immune
checkpoint inhibitors, including pruritus, rash, vitiligolike depig-
mentation, and lichenoid, cytotoxic, and autoimmune bullous
reactions.4 Interestingly, appearance of these adverse effects,
especially vitiligo, is associated with a superior outcome and
treatment response.5
Panniculitis is a group of inflammatory disorders of the subcu-
taneous fat tissue. Diagnosis can be challenging because different
forms of panniculitis may present with overlapping clinical find-
ings. Panniculitis can either be classified clinically based on the
cause (eg, infection, inflammation, trauma, enzymatic destruction,
deposition, or cancer) or histologically as lobular or septal pannicu-
litis with or without concomitant vasculitis. As for drug-induced
panniculitis, clinical and histopathological features of drug-
induced panniculitis are indistinguishable from those associated
with other agents, and only the history of previous drug intake or
clinical improvement after drug treatment interruption may prove
a causative relationship.6
Erythema nodosum (EN) is the most common type of pan-
niculitis located on the anterior surface of the lower extremities.
Mostly idiopathic in origin, EN may indicate an underlying system-
atic disease such as tuberculosis, deep bacterial and/or fungal
infection, inflammatory bowel disease, or cancer. Erythema nodo-
sum represents the cutaneous manifestation of sarcoidosis. Histo-
logically, septal panniculitis can present without vasculitis and with
radial granulomas. Erythema nodosum is also reported to be
the most common drug-induced panniculitis.7
In the setting of immune checkpoint inhibitors used for cell-
mediated immunity, few reports in the literature have described a
sarcoidlike granulomatous panniculitis.7-9 The typical histological
pattern includes partly granulomatous reactions with mixed
septal and lobular inflammatory infiltrate with lymphocytes and
epithelioid histiocytes.
Herein, we report a case of lobular panniculitis without vascu-
litis. Lobular panniculitis is usually considered in connective tissue
diseases, such as systemic lupus erythematosus, pancreatic dis-
eases or α-1 antitrypsin deficiency. Other histopathologic differen-
tial diagnoses include infection, trauma, or subcutaneous T-cell
lymphoma.10 All of these differential diagnoses were ruled out
through diagnostic workup in the present case. The absence of
tumor cells in the biopsy specimen ruled out disease progression.
The treatment with nivolumab was continued unchanged,
and the patient achieved a complete metabolic response seen
in the routine follow-up 18F-FDG PET-CTs. As for the panniculitis,
the lesion regressed slowly without the need for systemic steroid
or treatment cessation.
With regard to the treatment approach for immunotherapy-
induced panniculitis, the lesions usually regress spontaneously or
after treatment with nonsteroidal anti-inflammatory drugs or oral
or topical steroids. Cessation of immunotherapy is not generally
necessary.
To our knowledge, this is the first case of an extensive lobular
panniculitis in a patient treated with an anti–PD-1 antibody. Until
recently, panniculitides associated with immunotherapeutic
agents have not been extensively described. Because inconclusive
FDG-avid lesionsmay simulate disease progression, recognition of
these adverseeffects is important, andhistopathologicalworkup is
mandatory to ensure adequate treatment and prevent unneces-
sary treatment discontinuation.
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